Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of intravenous DFF (rhDNase I) in men with oligoasthenoteratozoospermia
MOH_2024-12-04_013779Phase 2Not yet recruiting
- Sponsor
- PeriNess
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dornase alfa in male infertility and oligoasthenoteratospermia (OAT), sponsored by PeriNess. Primary endpoint: Responder rate based on semen quality improvement. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
dornase alfa
03
Conditions
male infertilityoligoasthenoteratospermia (OAT)
Beyond the preview
Go deeper on MOH_2024-12-04_013779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-12-04_013779.